Drew Moghanaki, Professor and Chief of Thoracic Oncology at the David Geffen School of Medicine at UCLA, shared on LinkedIn:
“I’m surprised that more radiation oncologists and medical physicists aren’t discussing this issue. At UCLA, we’ve long recognized the fundamental limitations of 4DCT – limitations that may be contributing to higher-than-expected treatment failures after lung SBRT. That’s why our team transitioned to 5DCT in 2019, leading to extraordinary tumor control rates over 98%.
It’s time we started a broader conversation about the accuracy of today’s commercially available tumor motion management systems and how to get 5DCT into the hands of clinics worldwide.”
4DCT is long overdue for improvement
Authors: Erik Tryggestad et al.
See this impactful insight related to SBRT on OncoDaily:
New Paper Alert: SMART ONE Trial: Single Fraction MR-Guided SBRT for Visceral Tumors